Companies › Prana Therapies
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Immunology, Respiratory; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PRA-216 | – | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD); Atopic Dermatitis (AD); Mild to Moderate Asthma | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07245368 | PRA-216 | Phase 1 | Mild to Moderate Asthma | Respiratory | Jan 2027 |
| NCT07730281 | PRA-216 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | Respiratory | Jun 2027 |
| NCT07810777 | PRA-216 | Phase 2 | Atopic Dermatitis (AD) | Immunology | Sep 2027 |
No annotated target.
–
Enveda Therapeutics Cumberland Pharmaceuticals ReAlta Life Sciences Avalyn Pharma Toll Biotech Co. Ltd. (Beijing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.